IL301307B2 - Anti-A2AP antibodies and their uses - Google Patents

Anti-A2AP antibodies and their uses

Info

Publication number
IL301307B2
IL301307B2 IL301307A IL30130723A IL301307B2 IL 301307 B2 IL301307 B2 IL 301307B2 IL 301307 A IL301307 A IL 301307A IL 30130723 A IL30130723 A IL 30130723A IL 301307 B2 IL301307 B2 IL 301307B2
Authority
IL
Israel
Prior art keywords
ser
leu
vai
gly
thr
Prior art date
Application number
IL301307A
Other languages
English (en)
Hebrew (he)
Other versions
IL301307A (en
IL301307B1 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL301307A publication Critical patent/IL301307A/en
Publication of IL301307B1 publication Critical patent/IL301307B1/en
Publication of IL301307B2 publication Critical patent/IL301307B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
IL301307A 2020-09-15 2021-09-13 Anti-A2AP antibodies and their uses IL301307B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20196259 2020-09-15
PCT/EP2021/075038 WO2022058261A2 (en) 2020-09-15 2021-09-13 Novel anti-a2ap antibodies and uses thereof

Publications (3)

Publication Number Publication Date
IL301307A IL301307A (en) 2023-05-01
IL301307B1 IL301307B1 (en) 2025-05-01
IL301307B2 true IL301307B2 (en) 2025-09-01

Family

ID=72521424

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301307A IL301307B2 (en) 2020-09-15 2021-09-13 Anti-A2AP antibodies and their uses

Country Status (14)

Country Link
US (3) US20240010750A1 (https=)
EP (1) EP4214241A2 (https=)
JP (2) JP7454106B2 (https=)
KR (1) KR20230069171A (https=)
CN (1) CN116249719A (https=)
AR (1) AR123523A1 (https=)
AU (1) AU2021343834A1 (https=)
CA (1) CA3194792A1 (https=)
IL (1) IL301307B2 (https=)
MX (1) MX2023002984A (https=)
PE (1) PE20240214A1 (https=)
TW (1) TWI905264B (https=)
WO (1) WO2022058261A2 (https=)
ZA (1) ZA202405587B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4214241A2 (en) * 2020-09-15 2023-07-26 Bayer Aktiengesellschaft Novel anti-a2ap antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012329A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US20020086025A1 (en) * 1988-04-04 2002-07-04 Reed Guy L. Antibodies that bind to alpha2-antiplasmin crosslinked to fibrin which do not inhibit plasma alpha2-antiplasmin

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN101720368A (zh) 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
EP4214241A2 (en) * 2020-09-15 2023-07-26 Bayer Aktiengesellschaft Novel anti-a2ap antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086025A1 (en) * 1988-04-04 2002-07-04 Reed Guy L. Antibodies that bind to alpha2-antiplasmin crosslinked to fibrin which do not inhibit plasma alpha2-antiplasmin
WO1998012329A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MIMURO JUN ET AL,, MONOCLONAL ANTIBODIES TO DISCRETE REGIONS IN A2-PLASMIN INHIBITOR, 1 February 1987 (1987-02-01) *
REED G L,, FUNCTIONAL CHARACTERIZATION OF MONOCLONAL ANTIBODY INHIBITORS OF ALPHA2-ANTIPLASMIN THAT ACCELERATE FIBRINOLYSIS IN DIFFERENT ANIMAL PLASMAS, 1 June 1997 (1997-06-01) *
SAKATA Y ET AL,, CLOT LYSIS INDUCED BY A MONOCLONAL ANTIBODY AGAINST ALPHA2-PLASMIN INHIBITOR, 1 December 1989 (1989-12-01) *
SINGH SATISH ET AL,, RELEASING THE BRAKES ON THE FIBRINOLYTIC SYSTEM IN PULMONARY EMBOLI : UNIQUE EFFECTS OF PLASMINOGEN ACTIVATION AND [ALPHA]2-ANTIPLASMIN INACTIVATION, 14 March 2017 (2017-03-14) *

Also Published As

Publication number Publication date
AU2021343834A1 (en) 2023-04-13
CN116249719A (zh) 2023-06-09
JP7454106B2 (ja) 2024-03-21
AR123523A1 (es) 2022-12-14
KR20230069171A (ko) 2023-05-18
MX2023002984A (es) 2023-04-10
US20240034810A1 (en) 2024-02-01
US20240010750A1 (en) 2024-01-11
WO2022058261A3 (en) 2022-06-16
PE20240214A1 (es) 2024-02-16
TW202227505A (zh) 2022-07-16
US12215168B2 (en) 2025-02-04
ZA202405587B (en) 2025-05-28
IL301307A (en) 2023-05-01
WO2022058261A2 (en) 2022-03-24
IL301307B1 (en) 2025-05-01
US20240166766A1 (en) 2024-05-23
JP2023541179A (ja) 2023-09-28
BR112023002800A2 (pt) 2023-03-21
TWI905264B (zh) 2025-11-21
JP2024063234A (ja) 2024-05-10
EP4214241A2 (en) 2023-07-26
CA3194792A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
US20210403600A1 (en) Antibodies to coagulation factor xia and uses thereof
JP2024054266A (ja) 組織因子経路インヒビター抗体およびその使用
AU2018203753A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
CA2827091A1 (en) Pcsk9 antagonists
CN102325795A (zh) 针对组织因子途径抑制剂的抗体
AU2009279197A1 (en) Compositions and methods for antibodies targeting complement protein C5
JP2022536358A (ja) ナトリウム利尿ペプチド受容体１抗体及び使用方法
US20240052042A1 (en) Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
US12215168B2 (en) Anti-A2AP antibodies and uses thereof
US20210395390A1 (en) Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
KR20230162800A (ko) 항-sema3a 항체 및 그의 용도
CA2824885A1 (en) Binding proteins to inhibitors of coagulation factors
RU2844816C1 (ru) Новые антитела против a2ap и их применение
HK40091539A (zh) 新的抗a2ap抗体及其用途
BR112023002800B1 (pt) Anticorpos anti-a2ap e seu método de produção, conjugado deanticorpo, sequências de ácido nucleico isoladas, vetor, composiçãofarmacêutica, seu uso, e kit
HK1255136B (en) Antibodies to coagulation factor xia and uses thereof